Related Experiment Video
Updated: Aug 7, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Advances in infection control: ventilator-associated pneumonia
1Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
Mechanically ventilated patients face a high risk of developing ventilator-associated pneumonia (VAP), a serious infection often caused by specific pathogens. Early diagnosis and treatment are crucial for improving patient outcomes and preventing mortality.
Area of Science:
- Critical Care Medicine
- Infectious Diseases
- Respiratory Medicine
Background:
- Nosocomial pneumonia is a significant risk for mechanically ventilated patients, with ventilator-associated pneumonia (VAP) affecting 6-52% and carrying high mortality rates (27-51%).
- High-risk organisms like Pseudomonas aeruginosa and Acinetobacter spp. contribute to increased mortality.
- The primary infection route is aspiration of oropharyngeal secretions, though other routes exist.
Purpose of the Study:
- To highlight the significant risk and mortality associated with VAP in mechanically ventilated patients.
- To emphasize the importance of understanding VAP pathogenesis and risk factors for effective infection control.
- To underscore the need for improved diagnostic and early treatment strategies to enhance patient outcomes.
Main Methods:
- Review of existing literature on VAP incidence, mortality, causative pathogens, and transmission routes.
- Analysis of diagnostic challenges and the impact of timely treatment.
- Discussion of the role of clinical trials in evaluating preventive and therapeutic measures.
Main Results:
- VAP incidence ranges from 6% to 52% in mechanically ventilated patients, with attributable mortality between 27% and 51%.
- Gram-negative pathogens (40-60%) and gram-positive pathogens (15-20%) are common, often leading to polymicrobial infections.
- Early appropriate treatment is associated with improved patient outcomes.
Conclusions:
- Understanding VAP pathogenesis and risk factors is critical for developing effective infection control strategies.
- Accurate and timely diagnosis is essential for improving patient outcomes.
- Further clinical trials are needed to assess current and future preventive and therapeutic interventions for VAP.
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Mechanical Ventilation III: Noninvasive Ventilation
Noninvasive Positive-Pressure Ventilation (NIPPV)
Pneumonia I: Introduction

